Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Indonesian Mega-Farm Drives Surge in Deforestation - 2Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- 3Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- 4Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- 5Jennifer Lawrence and Josh Hutcherson to reprise their roles for new 'Hunger Games' movie 'Sunrise on the Reaping'
- Polar bears are rewiring their own genetics to survive a warming climate
- Becoming the best at Discussion: Individual Procedures
- NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
